A Phase 3 study (NCT03661320) investigating nivolumab in participants with muscle-invasive bladder cancer (MIBC) reached its primary completion on 2026-02-16. The trial compares chemotherapy alone versus chemotherapy plus nivolumab or nivolumab and BMS-986205, followed by continued therapy after surgery.
Background
This study focuses on Urinary Bladder Neoplasms, specifically Muscle-Invasive Bladder Cancer. Nivolumab is an immunotherapy drug that has been investigated across various cancer types.
Trial design
The study (NCT03661320) is a Phase 3 trial with an enrollment of 855 participants. It is designed to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone. The interventions include nivolumab, gemcitabine, and cisplatin. The primary outcomes for this study were not detailed in the provided data.
What this means
The primary completion of a Phase 3 clinical trial signifies that the last participant has been examined or received an intervention for the purposes of the primary outcome measure. For the nivolumab trial in muscle-invasive bladder cancer, this milestone indicates that data collection for the main endpoints is complete, moving the study closer to analysis and potential reporting of results. These findings will be crucial for understanding the potential role of nivolumab in the treatment paradigm for MIBC.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03661320, titled "A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Su", was posted with a primary completion date of 2026-02-16 on clinicaltrials.gov.